Aptevo Therapeutics Inc.
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.46% | 6.23% | -6.93% | 19.45% | 25.98% |
| Total Depreciation and Amortization | -46.15% | -42.45% | -38.79% | -31.71% | -39.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -159.71% | -74.97% | -120.11% | -67.25% | -41.29% |
| Change in Net Operating Assets | -22.24% | 36.45% | 214.77% | 27.01% | -125.06% |
| Cash from Operations | -15.28% | 1.14% | -9.63% | 16.31% | -28.11% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 261.81% | -- | 120.47% | 13.01% | 725.36% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 261.90% | -- | 120.62% | 13.01% | 725.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 432.92% | 1.19% | 143.54% | 83.49% | 49.47% |